Myasthenia gravis: mechanisms and management.
Myasthenia gravis is an autoimmune disease of known cause: an antibody to a specific molecule of defined structure. As long as the abnormality leading to the antibody response remains elusive, however, so will ideal treatment. In the meantime, most patients given proper management can lead normal or near-normal lives; prognosis is surprisingly good, and mortality should approach zero.
D000109:Acetylcholine / Q000502:physiology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000906:Antibodies / Q000502:physiology; D001327:Autoimmune Diseases / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009045:Motor Endplate / Q000503:physiopathology; D009157:Myasthenia Gravis / Q000503:physiopathology / Q000628:therapy*; D010956:Plasmapheresis; D011247:Pregnancy; D011950:Receptors, Cholinergic / Q000502:physiology; D013934:Thymectomy
D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D000906:Antibodies; D011950:Receptors, Cholinergic; D000109:Acetylcholine